Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE–(BUSINESS WIRE)–
The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible breaches of fiduciary duty and other violations of law in its transaction with Merck.
Click here to learn how to join our investigation and obtain additional information or contact us at [email protected] or toll-free: 866-264-3995. There is no cost or obligation to you.
In the transaction, shareholders of SpringWorks will receive only $47 per share in cash, which represents an equity value of approximately $3.9 billion.
SpringWorks insiders will receive substantial benefits as part of change of control arrangements.
The transaction agreement unreasonably limits competing transactions for SpringWorks by imposing a significant penalty if SpringWorks accepts a competing bid. We are investigating the conduct of the SpringWorks board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.
We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250428210745/en/
Ademi & Fruchter LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001
KEYWORDS: United States North America Wisconsin
INDUSTRY KEYWORDS: Class Action Lawsuit Professional Services Legal
MEDIA:
| Logo |
 |